Liquid-phase Separations Coupled with Ion Mobility-mass Spectrometry for Next-generation Biopharmaceutical Analysis

Overview

Journal Expert Rev Proteomics

Publisher Informa Healthcare

Date 2024 Jun 27

PMID 38934922

Authors

Devin M Makey

Brandon T Ruotolo

Affiliations

Soon will be listed here.

Abstract

Introduction: The pharmaceutical industry continues to expand its search for innovative biotherapeutics. The comprehensive characterization of such therapeutics requires many analytical techniques to fully evaluate critical quality attributes, making analysis a bottleneck in discovery and development timelines. While thorough characterization is crucial for ensuring the safety and efficacy of biotherapeutics, there is a need to further streamline analytical characterization and expedite the overall timeline from discovery to market.

Areas Covered: This review focuses on recent developments in liquid-phase separations coupled with ion mobility-mass spectrometry (IM-MS) for the development and characterization of biotherapeutics. We cover uses of IM-MS to improve the characterization of monoclonal antibodies, antibody-drug conjugates, host cell proteins, glycans, and nucleic acids. This discussion is based on an extensive literature search using Web of Science, Google Scholar, and SciFinder.

Expert Opinion: IM-MS has the potential to enhance the depth and efficiency of biotherapeutic characterization by providing additional insights into conformational changes, post-translational modifications, and impurity profiles. The rapid timescale of IM-MS positions it well to enhance the information content of existing assays through its facile integration with standard liquid-phase separation techniques that are commonly used for biopharmaceutical analysis.

References

Masson G, Jenkins M, Burke J . An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery. Expert Opin Drug Discov. 2017; 12(10):981-994. DOI: 10.1080/17460441.2017.1363734. View

Valentine S, Ewing M, Dilger J, Glover M, Geromanos S, Hughes C . Using ion mobility data to improve peptide identification: intrinsic amino acid size parameters. J Proteome Res. 2011; 10(5):2318-29. PMC: 3138335. DOI: 10.1021/pr1011312. View

Tomczyk N, Giles K, Richardson K, Ujma J, Palmer M, Nielsen P . Mapping Isomeric Peptides Derived from Biopharmaceuticals Using High-Resolution Ion Mobility Mass Spectrometry. Anal Chem. 2021; 93(49):16379-16384. DOI: 10.1021/acs.analchem.1c02834. View

Mallick P, Kuster B . Proteomics: a pragmatic perspective. Nat Biotechnol. 2010; 28(7):695-709. DOI: 10.1038/nbt.1658. View

Juliano B, Keating J, Li H, Anders A, Xie Z, Ruotolo B . Development of an Automated, High-Throughput Methodology for Native Mass Spectrometry and Collision-Induced Unfolding. Anal Chem. 2023; 95(45):16717-16724. PMC: 11081713. DOI: 10.1021/acs.analchem.3c03788. View

Reilly L, Lara E, Ramos D, Li Z, Pantazis C, Stadler J . A fully automated FAIMS-DIA mass spectrometry-based proteomic pipeline. Cell Rep Methods. 2023; 3(10):100593. PMC: 10626189. DOI: 10.1016/j.crmeth.2023.100593. View

Wang Y, Li X, Liu Y, Richardson D, Li H, Shameem M . Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion. MAbs. 2016; 8(8):1477-1486. PMC: 5098434. DOI: 10.1080/19420862.2016.1226715. View

Vallejo D, Kang J, Coghlan J, Ramirez C, Polasky D, Kurulugama R . Collision-Induced Unfolding Reveals Stability Differences in Infliximab Therapeutics under Native and Heat Stress Conditions. Anal Chem. 2021; 93(48):16166-16174. DOI: 10.1021/acs.analchem.1c03946. View

Gervais D, King D, Kanda P, Foote N, Elliott L, Brown P . Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry. Pharm Res. 2015; 32(11):3636-48. DOI: 10.1007/s11095-015-1722-2. View

10.

Burdett T, Nuseibeh S . Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies. Gene Ther. 2022; 30(3-4):323-335. DOI: 10.1038/s41434-022-00363-0. View

11.

Ghilardi N, Pappu R, Arron J, Chan A . 30 Years of Biotherapeutics Development-What Have We Learned?. Annu Rev Immunol. 2020; 38:249-287. DOI: 10.1146/annurev-immunol-101619-031510. View

12.

Dixit S, Polasky D, Ruotolo B . Collision induced unfolding of isolated proteins in the gas phase: past, present, and future. Curr Opin Chem Biol. 2017; 42:93-100. PMC: 5828980. DOI: 10.1016/j.cbpa.2017.11.010. View

13.

Yang F, Zhang J, Buettner A, Vosika E, Sadek M, Hao Z . Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control. MAbs. 2023; 15(1):2197668. PMC: 10114992. DOI: 10.1080/19420862.2023.2197668. View

14.

Desligniere E, Ehkirch A, Botzanowski T, Beck A, Hernandez-Alba O, Cianferani S . Toward Automation of Collision-Induced Unfolding Experiments through Online Size Exclusion Chromatography Coupled to Native Mass Spectrometry. Anal Chem. 2020; 92(19):12900-12908. DOI: 10.1021/acs.analchem.0c01426. View

15.

May J, Knochenmuss R, Fjeldsted J, McLean J . Resolution of Isomeric Mixtures in Ion Mobility Using a Combined Demultiplexing and Peak Deconvolution Technique. Anal Chem. 2020; 92(14):9482-9492. DOI: 10.1021/acs.analchem.9b05718. View

16.

Kumar R, Guttman A, Rathore A . Applications of capillary electrophoresis for biopharmaceutical product characterization. Electrophoresis. 2021; 43(1-2):143-166. DOI: 10.1002/elps.202100182. View

17.

Alhazmi H, Albratty M . Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies. Pharmaceuticals (Basel). 2023; 16(2). PMC: 9967501. DOI: 10.3390/ph16020291. View

18.

Arndt J, Wormwood Moser K, Van Aken G, Doyle R, Talamantes T, DeBord D . High-Resolution Ion-Mobility-Enabled Peptide Mapping for High-Throughput Critical Quality Attribute Monitoring. J Am Soc Mass Spectrom. 2021; 32(8):2019-2032. DOI: 10.1021/jasms.0c00434. View

19.

Rohner E, Yang R, Foo K, Goedel A, Chien K . Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022; 40(11):1586-1600. DOI: 10.1038/s41587-022-01491-z. View

20.

Egli M, Manoharan M . Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023; 51(6):2529-2573. PMC: 10085713. DOI: 10.1093/nar/gkad067. View